Sanofi said its top-selling Lantus insulin treatment proved three times more likely than standard care to maintain targeted blood sugar levels in patients with pre-diabetes or early type 2 diabetes at high risk of heart disease
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment